Twelve adult @entity1 (median age 29.5  years) were started on Eltrombopag 25-50  mg/day for @entity1071 ( @entity1071 ) @entity882 . All @entity1 were having primary @entity882 after @entity1071 . No @entity1 had other secondary cause for @entity882 . Two @entity1 were allogenic subsets (1 acute @entity2800 i.e., @entity3052 and 1 @entity2150 ), and 10 were autologous transplants (3 multiple @entity1582 , 6 @entity706 and 1 @entity3052 ). Nine @entity1 were males, three were females. The median time of starting Eltrombopag was 21  days post-stem cell infusion (range day +17 to +60) at a median platelet count of 9,000/cmm (range 3,000-11,000/cmm). The median duration for treatment was 29  days. Median total dose of 812.5  mg was received by @entity1 and they had a median platelet increment of 36,000/cmm. We observed that there were no adverse effects in these @entity1 and there was a gradual increase in platelet count so that none of the @entity1 had any complication due to @entity882 . The cost of treatment was less than the cost of extended hospitalization and irradiated single donor platelet transfusion.

Safety and Efficacy of Eltrombopag in Post-hematopoietic Stem Cell Transplantation ( @entity1071 ) XXXX .

@entity1 :: ('9606', 'Species') :: ['patients', 'patient'] @entity1071 :: ('MESH:D008232', 'Disease') :: ['post-hematopoietic stem cell transplantation', 'HSCT'] @entity882 :: ('MESH:D013921', 'Disease') :: ['thrombocytopenia'] @entity706 :: ('MESH:D008223', 'Disease') :: ['lymphoma'] @entity2150 :: ('MESH:D000741', 'Disease') :: ['aplastic anemia'] @entity2800 :: ('MESH:D007951', 'Disease') :: ['myeloid leukemia'] @entity3052 :: ('MESH:D015470', 'Disease') :: ['AML'] @entity1582 :: ('MESH:D009101', 'Disease') :: ['myeloma']
@entity882 :: (MESH:D013921,Disease) :: ['Thrombocytopenia']
